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dioprotection like thrombectomy devices, distal embolization
devices, glucose insulin potassium infusion, adenosine, endo-
vascular cooling etc., have yielded equivocal results because of
delayed time to reperfusion. In the present study mechanical
reperfusion was established within 6 h of symptom onset,
hence ensuring reasonable reperfusion window period.
In our opinion this is an important landmark study
showing potential cardioprotective benefit of EIVBB in STEMI
patients undergoing primary PCI within 6 h and having no
contraindications for BB and it may play a vital role in the
future in shifting the guideline for IV beta-blocker from class
IIa to class I, especially in acute anterior wall MI with sym-
pathetic stimulation and Killip class  II. The 20% greater
reduction in infarct size above that was achieved by
mechanical reperfusion offers great hope. Hence EIVBB can
be regarded as an asset with certainty for cardioprotection.
Well-designed RCTs aiming to achieve improvement in hard
clinical outcomes with EIVBB in STEMI patients is the need of
the hour.r e f e r e n c e s
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Objectives: The aim of this observational, multicenter
study was to describe the outcome of very elderly patients
undergoing percutaneous coronary intervention (PCI).
Background: There is a paucity of data among non-
agenarians undergoing PCI.
Methods: All consecutive patients 90 years of age or older
undergoing PCI with stent implantation between April 2002
and June 2009 were included in the study. The primary end-
point was the long term rate of net adverse cardiac events
(NACE), that is, death, myocardial infarction (MI), target lesion
revascularization, and life threatening or major bleedings.
Results: One hundred forty-six nonagenarians were divi-
ded in three groups according to clinical setting: 27 (group A)
stable angina or silent ischemia, 85 (group B) unstable angina
or non-ST elevation MI, and 34 (group C) with ST elevation MI
(STEMI). At 30 days, the incidence of NACE was significantly
lower in patients in Group A vs. B or C (0% vs. 17.3% vs. 31.2%,
p ¼ 0.006), and the frequency of definite stent thrombosis was
higher in Group C vs. A or B (9.4% vs. 0% vs. 0%, p ¼ 0.007),
respectively. Up to a median follow up of 24 months, NACE
rate was 33.3% in group A, 49.3% in group B, and 50% in group
C (p ¼ 0.32). There were no significant differences between
groups in the individual components of the primary endpoint.
Conclusions: PCI in nonagenarians is safe and feasiblewith
acceptable major bleeding rates. However, long term results
show high mortality rates particularly in the STEMI group.1. Perspective
1.1. NINETY e age not a PENALTY
With an increase in life expectancy, there is a significant
increase in the elderly and very elderly population. This trend
is expected to increase further in the coming years. CAD is an
important cause of mortality in the very elderly age group.
Elderly age is an independent risk factor for short term mor-
tality in CAD, especially STEMI patients. Atypical symptoms,
late presentation, lack of timely medical advice and trans-
portation to hospitals with critical care units put this pop-
ulation at high risk with increased complications and adverse
effects. Elderly and very elderly patients are usually excluded
from the major trials of revascularization and optimal treat-
ment strategies and outcomes in this subgroup are less clear.
Thrombolytic therapy was thought to be associated with
increased bleeding risks in elderly, especially intracranial
bleeding, as compared to primary PCI, but major trials testing
this hypothesis had failed to prove it.1,2 In fact, registry data
show that less than 50% of the elderly patients receive any
form of revascularization therapy despite suggested mortality
benefit. About 20e30% of these patients undergoing PCI
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with high risk features like ventricular arrhythmias and con-
gestive cardiac failure.3 Dynina et al reported that patients
with age > 85 years undergoing PCI more commonly devel-
oped stroke and renal failure requiring dialysis as compared to
patients with age < 85 years.4 In that study it was also shown
that age was not an independent risk factor for excess in
hospital mortality in the very elderly cohort.4
In the present study, both short term and long term
mortality was highest in STEMI patients as compared to
UA/NSTEMI and stable angina group. Antonsen et al showed a
similar finding with the highest short term and 1-year mor-
tality among elderly STEMI patients as compared to stable
angina patients.3
The most common type of stent used in this study in all
three groups (STEMI/NSTEMI/stable angina) was BMS as
compared to DES (67% vs. 22.6%) and only 13.3% of patients in
STEMI group had received DES. In spite of this it did not reveal
any difference in TLR rates. One of the reasons for this finding
could be inadequate power of the study to elucidate difference
in TLR between BMS and DES. This is in contrast to another
study which has shown that usage of DES in elderly patients
has increased from 0.0% to 60.3% from the year 2002e2008 and
TLR has reduced from 7.1% to 2.5% during that corresponding
period.3
Both at short term and long term follow up, the occurrence
of stent thrombosis (ST) was higher in STEMI patients. STEMI
is a known independent risk factor for ST both in young and
elderly patients. Hypercoagulable state associated with STEMI
is the possible explanation for this finding and due to per-
ceived higher risk of ST, DES is being used in only in less than
one third of elderly STEMI patients.3
Though the present study is only an observational study,
the enthusiasm for conducting randomized controlled trials
in elderly CAD patients undergoing PCI was already shattered
by premature termination of two such trials in the elderly,
Senior-PAMI and TRIANA trials, due to slow enrolment. This
study is one of the very few studies available in such a very
elderly age group and this is the only study showing long term
outcomes upto 2 years of follow up. It also gives positive hope
on bleeding risks in elderly.
In our opinion, with increasing aging of population and
increased access to healthcare, we are likely to encounter
more and more patients with CAD requiring intervention in
the very elderly cohort. We should not leave such patients at
the mercy of God and in spite of perceived increased risk, we
should try to do our best for such patients. The present study
supports this observation and shows that PCI is feasible in the
very elderly with acceptable mortality, NACE and bleeding
risks, with highest events occurring in STEMI group (like in
any other age group).r e f e r e n c e s
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2132e2140.1. Background
Catheter-based renal artery sympathetic denervation has
emerged as a novel therapy for treatment of patients with
drug-resistant hypertension. Initial studies were performed
using a single electrode radiofrequency catheter, but recent
advances in catheter design have allowed the development of
multi-electrode systems that can deliver lesions with a pre-
determined pattern. This study was designed to evaluate the
safety and efficacy of the EnligHTN, a multi-electrode system.2. Methods and results
We conducted the first-in-human, prospective, multicentre,
non-randomized study in 46 patients (67% male, mean age
60 years, and mean baseline office blood pressure 176/
96 mmHg) with drug-resistant hypertension. The primary
efficacy objective was change in office blood pressure from
baseline to 6 months. Safety measures included all adverse
events with a focus on the renal artery and other vascular
